Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc. JAZZ and Azur Pharma Limited today announced that the companies have agreed to combine in an all-stock transaction that creates a specialty pharmaceutical company incorporated in Ireland with a diversified portfolio of products currently marketed in the United States. The combined company would be named Jazz Pharmaceuticals plc. Azur Pharma is a privately-held, profitable specialty pharmaceutical company headquartered in Dublin, Ireland with US operations in Philadelphia. The company markets ten specialty pharmaceutical products in the US in the central nervous system and women's health areas, with expected 2011 net sales of approximately $95 to $100 million.